# This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

(FILE 'HOME' ENTERED AT 09:14:20 ON 11 JAN 2003)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, CANCERLIT' ENTERED AT 09:14:46 ON 11 JAN 2003

L1 1327 S ((NILSON L?) OR (POTTER H?) OR (ARENDASH G?))/AU

L2 7605 S ANTICHYMOTRYPSIN
L3 90 S L1 AND L2

L4 170602 S TRANSGENIC
L5 10 S L3 AND L4

L6 4 DUP REM L5 (6 DUPLICATES DEMOVED)

L6 4 DUP REM L5 (6 DUPLICATES REMOVED)
L7 46 S MUCKE L?/AU AND ABRAHAM C?/AU
L8 10 S L2 AND L7

L9 4 DUP REM L8 (6 DUPLICATES REMOVED) L10 109110 S TRANSGENIC(S) (MOUSE OR MICE)

L11 48 S L2 AND L10

L12 25 DUP REM L11 (23 DUPLICATES REMOVED)





L Number	Hits	Search Text	DB	Time stamp
1	7049	NILSSON.IN. POTTER.IN. ARENDASH.IN.	USPAT;	2003/01/11 08:49
			US-PGPUB;	
			EPO; JPO;	
			DERWENT	
2	1053327	antichymotrypsin act	USPAT;	2003/01/11 08:49
			US-PGPUB;	
			EPO; JPO;	
			DERWENT	
3	535	antichymotrypsin	USPAT;	2003/01/11 08:49
			US-PGPUB;	
			EPO; JPO;	
			DERWENT	
4	21	(NILSSON.IN. POTTER.IN. ARENDASH.IN.) and antichymotrypsin	USPAT;	2003/01/11 08:51
1			US-PGPUB;	
			EPO; JPO;	
			DERWENT	
5	24835	transgenic	USPAT;	2003/01/11 08:51
			US-PGPUB;	
			EPO; JPO;	
		(244 666) 124 067777 24 25 25 25 25 25 25 25 25 25 25 25 25 25	DERWENT	
6	4	((NILSSON.IN. POTTER.IN. ARENDASH.IN.) and antichymotrypsin)	USPAT;	2003/01/11 08:55
		and transgenic	US-PGPUB;	
i l			ÉPO; JPO;	
7	125	and take we as a made and demand on the	DERWENT	2002/01/11 00 55
'	123	antichymotrypsin and transgenic	USPAT;	2003/01/11 08:55
			US-PGPUB;	
			EPO; JPO; DERWENT	
8	173627	mouse	USPAT:	2003/01/11 08:55
0	173027	House	US-PGPUB;	2003/01/11 08:33
			EPO: JPO:	
			DERWENT	
9	9167	transgenic with mouse	USPAT;	2003/01/11 08:56
1	3.07	than speare with mouse	US-PGPUB;	2003/01/11 00.30
			EPO; JPO;	
			DERWENT	
10	105	antichymotrypsin and (transgenic with mouse)	USPAT;	2003/01/11 08:56
		, ,, , ,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	US-PGPUB;	2220701711 00.50
			EPO: JPO:	
			DERWENT	



ExPASy Home page	Site Map	Search ExPASy	Contact us	SWISS-PROT
Hosted by NCS	C US Mirror site	s: Bolivia Canada China K	orea Switzerland T	`aiwan

NiceProt View of SWISS-PROT: P01011

Printer-friendly view Quick BlastP search

[General] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

General information about the co	nûry			
Entry name	AACT_HUMAN			
Primary accession number	P01011			
Secondary accession number	Q13703			
Entered in SWISS-PROT in	Release 01, July 1986			
Sequence was last modified in	Release 19, August 1991			
Annotations were last modified in	Release 41, June 2002			
Name and origin of the protein				
Protein name	Alpha-1-antichymotrypsin [Precursor]			
Synonym	ACT			
Gene name	SERPINA3 or AACT			
From	Homo sapiens (Human) [TaxID: 9606]			
Taxonomy	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
References				
Chandra T., Stackhouse R., Ki "Sequence homology between Biochemistry 22:5055-5061(1)  [2] SEQUENCE FROM NUCLEI MEDLINE=94063919; PubModeline Poller W., Faber JP., Weidin "A leucine-to-proline substitut lung disease."; Genomics 17:740-743(1993).  [3] SEQUENCE FROM NUCLEI TISSUE=Brain, and Skin; Strausberg R.; Submitted (JUL-2001) to the E  [4] SEQUENCE OF 87-129 FROM MEDLINE=90110106; PubModeline H., Wang Z., Nickbarg	ed=6606438; [NCBI, ExPASy, EBI, Israel, Japan] dd V.J., Robson K.J.H., Woo S.L.C.; human alpha 1-antichymotrypsin, alpha 1-antitrypsin, and antithrombin III."; p83).  C ACID, AND VARIANTS BOCHUM-1 AND BONN-1. ed=8244391; [NCBI, ExPASy, EBI, Israel, Japan] ger S., Tief K., Scholz S., Fischer M., Olek K., Kirchgesser M., Heidtmann HH.; ion causes a defective alpha 1-antichymotrypsin allele associated with familial obstructive  C ACID.  MBL/GenBank/DDBJ databases. M NUCLEIC ACID. ed=2404007; [NCBI, ExPASy, EBI, Israel, Japan] E.B., McLarney S., Naidoo N., Schoenberger O.L., Johnson J.L., Cooperman B.S.; ion, and biological activity of recombinant native and variant human alpha (1990).			
Submitted (OCT-1989) to the [6] SEQUENCE OF N-TERMINU MEDLINE=89323223; PubMo Lindmark B., Hilja H., Alan R.	ed=2787670; [NCBI, ExPASy, EBI, Israel, Japan]			



Biochim. Biophys. Acta 997:90-95(1989).

[7] ACTIVE SITE.

MEDLINE=84032476; PubMed=6556193; [NCBI, ExPASy, EBI, Israel, Japan]

Morii M., Travis J.;

"Amino acid sequence at the reactive site of human alpha 1-antichymotrypsin."; J. Biol. Chem. 258:12749-12752(1983).

[8] X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS).

MEDLINE=91202538; PubMed=2016749; [NCBI, ExPASy, EBI, Israel, Japan]

Baumann U., Huber R., Bode W., Grosse D., Lesjak M., Laurell C.-B.;

"Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7-A resolution and its comparison with other serpins.";

J. Mol. Biol. 218:595-606(1991).

[9] X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS).

MEDLINE=96433079; PubMed=8836107; [NCBI, ExPASy, EBI, Israel, Japan]

Lukacs C.M., Zhong J.Q., Plotnick M.I., Rubin H., Cooperman B.S., Christianson D.W.;

"Arginine substitutions in the hinge region of antichymotrypsin affect serpin beta-sheet rearrangement.";

Nat. Struct. Biol. 3:888-893(1996).

[10] X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).

MEDLINE=98198038; PubMed=9521649; [NCBI, ExPASy, EBI, Israel, Japan]

Lukacs C.M., Rubin H., Christianson D.W.;

"Engineering an anion-binding cavity in antichymotrypsin modulates the 'spring-loaded' serpin-protease interaction."; Biochemistry 37:3297-3304(1998).

[11] VARIANT ISEHARA-1.

MEDLINE=92316200; PubMed=1618300; [NCBI, ExPASy, EBI, Israel, Japan]

Tsuda M., Sei Y., Yamamura M., Yamamoto M., Shinohara Y.;

"Detection of a new mutant alpha-1-antichymotrypsin in patients with occlusive-cerebrovascular disease."; FEBS Lett. 304:66-68(1992).

[12] VARIANT BONN-1.

MEDLINE=92292844; PubMed=1351206; [NCBI, ExPASy, EBI, Israel, Japan]

Poller W., Faber J.-P., Scholz S., Weindinger S., Bartholome K., Olek K., Eriksson S.;

"Mis-sense mutation of alpha 1-antichymotrypsin gene associated with chronic lung disease.";

Lancet 339:1538-1538(1992).

#### Comments

- FUNCTION: ALTHOUGH ITS PHYSIOLOGICAL FUNCTION IS UNCLEAR, IT CAN INHIBIT NEUTROPHIL
  CATHEPSIN G AND MAST CELL CHYMASE, BOTH OF WHICH CAN CONVERT ANGIOTENSIN I TO THE
  ACTIVE ANGIOTENSIN II.
- SUBCELLULAR LOCATION: Extracellular.
- TISSUE SPECIFICITY: PLASMA. SYNTHESIZED IN THE LIVER. LIKE THE RELATED ALPHA-1-ANTITRYPSIN, ITS CONCENTRATION INCREASES IN THE ACUTE PHASE OF INFLAMMATION OR INFECTION.
- *DISEASE*: DEFICIENCY IN ACT CAN BE A CAUSE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR OF OCCLUSIVE CEREBROVASCULAR DISEASE.
- MISCELLANEOUS: ALPHA-1-ANTICHYMOTRYPSIN CAN BIND DNA.
- SIMILARITY: BELONGS TO THE SERPIN FAMILY.
- CAUTION: IT IS UNCERTAIN WHETHER MET-1 OR MET-4 IS THE INITIATOR.

#### Copyreleint

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a> or send an email to license@isb-sib.ch).

### Cross-references



EMBL	K01500; AAA51543.1; [EMBL / GenBank / DDBJ] [CoDingSequence] X68733; CAA48671.1; ALT_INIT. [EMBL / GenBank / DDBJ] [CoDingSequence] X68734; CAA48671.1; JOINED. [EMBL / GenBank / DDBJ] [CoDingSequence] X68735; CAA48671.1; JOINED. [EMBL / GenBank / DDBJ] [CoDingSequence] X68736; CAA48671.1; JOINED. [EMBL / GenBank / DDBJ] [CoDingSequence] X68737; CAA48671.1; JOINED. [EMBL / GenBank / DDBJ] [CoDingSequence] BC003559; AAH03559.1; [EMBL / GenBank / DDBJ] [CoDingSequence] BC010530; AAH10530.1; [EMBL / GenBank / DDBJ] [CoDingSequence] J05176; AAA51560.1; [EMBL / GenBank / DDBJ] [CoDingSequence] A01246; ITHUC.
PIR	A34934; A34934. S14806; S14806.
PDB	2ACH; 15-JUL-93. [ExPASy / RCSB] 3CAA; 25-FEB-98. [ExPASy / RCSB] 4CAA; 25-FEB-98. [ExPASy / RCSB] 1AS4; 25-FEB-98. [ExPASy / RCSB] Detailed list of linked structures.
GlycoSuiteDB SWISS-2DPAGE	<u>P01011;</u>
Siena-2DPAGE	<u>P01011;</u> HUMAN. P01011;
Genew	HGNC:16; SERPINA3.
MIM	107280 [NCBI / EBI].
GeneCards	SERPINA3.
GeneLynx	SERPINA3; Homo sapiens.
SOURCE	SERPINA3; Homo sapiens.
Ensembl	P01011; Homo sapiens. [Entry / Contig view]
InterPro	IPR000215; Serpin. Graphical view of domain structure.
Pfam	PF00079; serpin; 2.
SMART	SM00093; SERPIN; 1.
PROSITE	PS00284; SERPIN; 1.
ProDom	[Domain structure / List of seq. sharing at least 1 domain].
BLOCKS	<u>P01011</u> .
ProtoNet	<u>P01011</u> .
ProtoMap	<u>P01011</u> .
PRESAGE	<u>P01011</u> .
DIP	<u>P01011</u> .
ModBase	P01011.
Kaywords	
Serpin; Serine pr Disease mutation	otease inhibitor; Plasma; Acute phase; Glycoprotein; Signal; 3D-structure; Polymorphism;
Features	
	rom To Length Description
SIGNAL	1 23 23
	24 423 400 ALPHA-1-ANTICHYMOTRYPSIN.
ACT_SITE 3	83 384 REACTIVE BOND.
CARBOHYD	93 93 N-LINKED (GLCNAC).
	27 127 N-LINKED (GLCNAC).
	35 237 3
VARIANT	9 9 A -> T (IN DBSNP:4934) [NCBI/Ensembl]. /FTId=VAR_006973.

4	
4	
•	

VARIAN	r .	78 7	8
VARIANT	r <u>16</u>	57 16	7
VARIANT	25	52 25	2
VARIANT	40	1 40	1
VARIANT	40	7 40	7
CONFLIC'	<u> </u>	9 69	9
CONFLIC	Г <u>10</u>	2 116	5
CONFLICT	Г 12.	3 128	
CONFLICT			•
CONFLICT			
CONFLICT			
HELIX	49		1.0
TURN	69		19
STRAND	73		2
HELIX	77		3
TURN	89		12
HELIX	93	90 102	2
TURN	103		10
TURN	107	104	2
HELIX	112	126	3
STRAND	128	129	15
STRAND	134	144	2
TURN	145	146	11
HELIX	151	161	2
STRAND	164	168	11
TURN	170	171	5
HELIX	173	187	2
TURN	188	190	15
TURN	201	202	3
STRAND	. 203	217	2
HELIX	223	225	15
STRAND	227	234	3
TURN	235	236	8
STRAND	237	256	2 20
TURN	257	260	4
STRAND	261	268	8
STRAND	272	279	8
TURN	281	282	2
HELIX	284	289	6
TURN	290	290	1
HELIX	293	302	10
STRAND	304	314	11
STRAND	316	323	8
HELIX	325	330	6
TURN	331	332	2
HELIX	335	337	3
TURN	339	340	2
HELIX	344	347	4
STRAND	352	365	14

L -> P (IN COPD; BOCHUM-1; DBSNP:1800463) [NCBI/Ensembl]. /FTId=VAR\_006974. A -> G. /FTId=VAR\_006975. P -> A (IN COPD; BONN-1). /FTId=VAR\_006976. M -> V (IN COPD; ISEHARA-1). /FTId=VAR\_006977. D -> G (IN DBSNP:10956) [NCBI/Ensembl]. /FTId=VAR\_011742. P -> L (IN REF.  $\underline{1}$ ). (IN REF.  $\underline{1}$ ). LRTLNQ -> RAPSIS (IN REF. 1). L -> P (IN REF.  $\underline{1}$ ). AVL -> VVS (IN REF. 1). KQA -> SKPRACIKQWGSQ (IN REF. 1).



Feature aligner



Feature table viewer


1	

STRAND	369	382	14
STRAND	391	394	4
STRAND	399	405	7
TURN	406	407	2
STRAND	413	417	5
TURN	420	421	2
			_

Sequence information	hm
----------------------	----

Length: 423 A of the unproce	A [This is the le ssed precursor]	ngth Molecular the MW of	weight: 47650 I the unprocessed		CRC64: <b>B002F94</b> 6	C86A8951 [This is a
10	) 2(		41	precursor	necksum on the se	quence]
MERMLPLLAL	GLLAAGFCPA	 	-		50 60   LA SANVDFAFSI	
70 	1 80	90	100	) 13	120	1
YKQLVLKAPD	KNVIFSPLSI	STALAFLSLG	   AHNTTLTEII	KGLKFNLTE	 ET SEAEIHOSFO	00 TO THE TOTAL OF
130	140	150	160	17	'0 180	He. He was s
			DRFTEDAKRL	YGSEAFATD	  F QDSAAAKKLI	Market, Modern
190	200	210	220	2,3	- 210	30° W.C. (1985)
		SQTMMVLVNY	IFFKAKWEMP	FDPQDTHQS	 R FYLSKKKWVM	GEOGRAM A MAG 2004
250	260	270	280 	29	- 300	escrite praiding control of the cont
		CTVVELKYTG	NASALFILPD	QDKMEEVEA	 M LLPETLKRWR	Party management of the control of t
310	320	330	340	350	300	All Annual Managers
370			LGIEEAFTSK	ADLSGITGA	NLAVSQVVHK	
ĺ	380	390	400	410		#C2N4046-4-00004C24
VE DEGI	easaatavKI	TLLSALVETR	TIVRFNRPFL	MIIVPTDTQN	   IFFMSKVTNP	- (486)
QA						1177 - 300 H. J.
						P01011 in <u>FASTA</u> format

View entry in original SWISS-PROT format View entry in raw text format (no links) Report form for errors/updates in this SWISS-PROT entry



Direct BLAST submission at EMBnet-CH/SIB (Switzerland)



Direct BLAST submission at NCBI (Bethesda, USA)



ScanProsite, MotifScan



Sequence analysis tools: <u>ProtParam</u>, <u>ProtScale</u>, <u>Compute</u> <u>pI/Mw</u>, <u>PeptideMass</u>, <u>PeptideCutter</u>, <u>Dotlet</u> (Java)



Feature table viewer (Java)



Search the SWISS-MODEL Repository

The second secon				
ExPASy Home page	Site Map	Search ExPASy	Contact us	<u>SWISS-PROT</u>